biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas
Company profile
Ticker
BRTX
Exchange
Website
CEO
Mark Weinreb
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Stem Cell Assurance, Inc.
SEC CIK
Corporate docs
IRS number
911835664
BRTX stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
19 Apr 24
EFFECT
Notice of effectiveness
19 Apr 24
S-1/A
IPO registration (amended)
12 Apr 24
S-1
IPO registration
3 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
12 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Feb 24
8-K
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
5 Feb 24
8-K
Regulation FD Disclosure
1 Feb 24
S-8
Registration of securities for employees
15 Nov 23
Latest ownership filings
4
Francisco Silva
10 Apr 24
4
Francisco Silva
20 Mar 24
4
LANCE ALSTODT
20 Mar 24
SC 13D/A
Broadrick Dale
6 Mar 24
SC 13D/A
Silva Francisco
15 Feb 24
SC 13D/A
ALSTODT LANCE
15 Feb 24
4
David A Rosa
15 Feb 24
4
Patrick F. Williams
15 Feb 24
4
Nickolay V. Kukekov
15 Feb 24
4
Robert Paccasassi
15 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.44 mm | 2.44 mm | 2.44 mm | 2.44 mm | 2.44 mm | 2.44 mm |
Cash burn (monthly) | (no burn) | 344.69 k | 1.03 mm | 1.39 mm | 392.57 k | 519.18 k |
Cash used (since last report) | n/a | 2.34 mm | 7.04 mm | 9.46 mm | 2.67 mm | 3.53 mm |
Cash remaining | n/a | 92.03 k | -4.60 mm | -7.02 mm | -233.74 k | -1.10 mm |
Runway (months of cash) | n/a | 0.3 | -4.4 | -5.0 | -0.6 | -2.1 |
Institutional ownership, Q2 2023
4.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 5 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.36 bn |
Total shares | 322.63 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 126.96 k | $559.88 mm |
Wealth Alliance | 44.32 k | $195.43 mm |
Geode Capital Management | 43.78 k | $193.05 mm |
Mariner | 26.67 k | $117.61 mm |
Two Sigma Advisers | 26.30 k | $115.98 mm |
STT State Street | 20.46 k | $90.22 mm |
SNEX StoneX | 14.88 k | $66.00 k |
WFC Wells Fargo & Co. | 11.56 k | $50.99 mm |
UBS UBS Group AG - Registered Shares | 3.08 k | $13.58 mm |
Steward Partners Investment Advisory | 2.00 k | $8.82 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Francisco Silva | Common Stock | Buy | Acquire P | No | No | 1.25 | 6,600 | 8.25 k | 155,759 |
8 Apr 24 | Francisco Silva | Common Stock | Buy | Acquire P | No | No | 1.17 | 1,232 | 1.44 k | 149,159 |
8 Apr 24 | Francisco Silva | Common Stock | Buy | Acquire P | No | No | 1.13 | 476 | 537.88 | 147,927 |
18 Mar 24 | Francisco Silva | Common Stock | Payment of exercise | Dispose F | No | No | 1.39 | 17,193 | 23.90 k | 147,451 |
18 Mar 24 | Lance Alstodt | Common Stock | Payment of exercise | Dispose F | No | No | 1.39 | 17,633 | 24.51 k | 171,872 |
9 Feb 24 | Broadrick Dale | Common Stock | Buy | Acquire P | Yes | No | 1.32 | 86,041 | 113.57 k | 477,972 |
8 Feb 24 | Broadrick Dale | Common Stock | Buy | Acquire P | Yes | No | 1.25 | 73,959 | 92.45 k | 391,931 |
8 Feb 24 | Broadrick Dale | Common Stock | Buy | Acquire P | No | No | 1.34 | 83,626 | 112.06 k | 447,045 |
7 Feb 24 | Broadrick Dale | Common Stock | Buy | Acquire P | No | No | 1.38 | 36,374 | 50.20 k | 363,419 |
News
Market-Moving news for April 16th
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Apr 24
Dominari Holdings And 2 Other Stocks Under $3 Insiders Are Buying
11 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
8 Apr 24
Press releases
Biotech Catches Major Premarket Bid Following FDA Clearance
16 Apr 24
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16 Apr 24
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
8 Apr 24
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
3 Apr 24
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
14 Feb 24